Tumor Necrosis Factor Blocker [EPC]

728863 reported adverse events

Drugs of this class: ETANERCEPT GOLIMUMAB INFLIXIMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 79444
1 INJECTION SITE PAIN 56328
2 ARTHRALGIA 43991
3 INJECTION SITE ERYTHEMA 41074
4 RHEUMATOID ARTHRITIS 39039
5 PAIN 38101
6 OFF LABEL USE 29427
7 FATIGUE 27838
8 PSORIASIS 26261
9 PAIN IN EXTREMITY 25101
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INJECTION SITE RECALL REACTION 481 0.9816
1 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 280 0.9756
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 735 0.8429
3 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1314 0.8423
4 RHEUMATOID FACTOR POSITIVE 1213 0.8092
5 C-REACTIVE PROTEIN ABNORMAL 2005 0.7875
6 INJECTION SITE MACULE 467 0.7343
7 SYNOVITIS 5148 0.6508
8 INJECTION SITE WARMTH 10374 0.6427
9 PEMPHIGUS 1676 0.6007
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]